Milan, Italy

Carlo Sclolastico

This inventor holds 1 USPTO granted patent. Top assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.a.. Active years: 1991.


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 1991

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Carlo Sclolastico: Innovator in Pharmaceutical Science

Introduction

Carlo Sclolastico is a notable inventor based in Milan, Italy. He has made significant contributions to the field of pharmaceutical science, particularly in the area of cognitive enhancers. His work focuses on developing compounds that can potentially improve learning and memory.

Latest Patents

Carlo Sclolastico holds a patent for a compound titled "(Pyrrolidin-2-one-1-yl) acetamides and enhancers of learning and memory." This patent includes the general formula (I) ##STR1##, wherein R is hydrogen or hydroxyl, and R1 is hydrogen, while R2 is selected from a specific group. This innovative compound aims to enhance cognitive functions, showcasing Sclolastico's commitment to advancing medical science.

Career Highlights

Sclolastico is associated with Sigma-Tau Industrie Farmaceutiche Riunite S.p.a., a prominent pharmaceutical company. His role at Sigma-Tau has allowed him to collaborate with other talented professionals in the industry, contributing to the development of groundbreaking pharmaceutical products.

Collaborations

Some of his notable coworkers include Maria Ornella Tinti and Orlando Ghirardi. Their collaborative efforts have played a crucial role in the research and development of innovative pharmaceutical solutions.

Conclusion

Carlo Sclolastico's work exemplifies the spirit of innovation in the pharmaceutical industry. His contributions, particularly in cognitive enhancement, highlight the importance of research and collaboration in advancing medical science.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…